Cargando…

A major genetic accelerator of cancer diagnosis: rs867228 in FPR1

Detalles Bibliográficos
Autores principales:	Sztupinszki, Zsofia, Le Naour, Julie, Vacchelli, Erika, Laurent-Puig, Pierre, Delaloge, Suzette, Szallasi, Zoltan, Kroemer, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801119/ https://www.ncbi.nlm.nih.gov/pubmed/33489470 http://dx.doi.org/10.1080/2162402X.2020.1859064

Ejemplares similares

Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer
por: Carbonnier, Vincent, et al.
Publicado: (2023)

The ambiguous role of FPR1 in immunity and inflammation
por: Vacchelli, Erika, et al.
Publicado: (2020)

A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
por: Le Naour, Julie, et al.
Publicado: (2022)

An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1)
por: Chiang, Shu-Fen, et al.
Publicado: (2021)

No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19
por: Petrazzuolo, Adriana, et al.
Publicado: (2020)

Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis
por: Le Naour, Julie, et al.
Publicado: (2023)

Trial watch: IDO inhibitors in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Trial watch: TLR3 agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

Improved Swiss-rolling method for histological analyses of colon tissue
por: Le Naour, Julie, et al.
Publicado: (2022)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)

FPR Ligands
por: Liu, Ying, et al.
Publicado: (2013)

Trial watch: Toll-like receptor ligands in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2023)

Cell Death Signaling and Anticancer Therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2011)

Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2
por: Zhuang, Youwen, et al.
Publicado: (2022)

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
por: Dillon, Kasia M., et al.
Publicado: (2022)

Characterization of unique PMEPA1 gene splice variants (isoforms d and e) from RNA Seq profiling provides novel insights into prognostic evaluation of prostate cancer
por: Sharad, Shashwat, et al.
Publicado: (2020)

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
por: Enot, David P., et al.
Publicado: (2018)

FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin
por: Pol, Jonathan G., et al.
Publicado: (2020)

Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2–Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages
por: Marutani, Takayuki, et al.
Publicado: (2021)

Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
por: Sztupinszki, Zsofia, et al.
Publicado: (2018)

The common promoter polymorphism rs11666254 downregulates FPR2/ALX expression and increases risk of sepsis in patients with severe trauma
por: Zhang, Han, et al.
Publicado: (2017)

A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice
por: Lévesque, Sarah, et al.
Publicado: (2019)

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
por: Castoldi, Francesca, et al.
Publicado: (2018)

N-Formylpeptides Induce Two Distinct Concentration Optima for Mouse Neutrophil Chemotaxis by Differential Interaction with Two N-Formylpeptide Receptor (Fpr) Subtypes: Molecular Characterization of Fpr2, a Second Mouse Neutrophil Fpr
por: Hartt, Jennifer K., et al.
Publicado: (1999)

Identification and validation of FPR1, FPR2, IL17RA and TLR7 as immunogenic cell death related genes in osteoarthritis
por: Ren, Tingting, et al.
Publicado: (2023)

Trial Watch: Immunostimulatory cytokines
por: Vacchelli, Erika, et al.
Publicado: (2012)

Trial Watch: Lenalidomide-based immunochemotherapy
por: Semeraro, Michaela, et al.
Publicado: (2013)

Microenvironment involved in FPR1 expression by human glioblastomas
por: Boer, J. C., et al.
Publicado: (2015)

FPR1 is the plague receptor on host immune cells
por: Osei-Owusu, Patrick, et al.
Publicado: (2019)

Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy
por: Lindgaard, Sidsel C., et al.
Publicado: (2022)

Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models
por: Sztupinszki, Zsófia, et al.
Publicado: (2016)

Trial watch: Oncolytic viruses for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Immunostimulatory cytokines
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial watch: Monoclonal antibodies in cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer
por: Miao, Chenkui, et al.
Publicado: (2022)

Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors
por: Sahgal, Pranshu, et al.
Publicado: (2023)

Trial watch: intratumoral immunotherapy
por: Humeau, Juliette, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_79vhnoqa1eg7shrosqcbkqcl5o